tetano
Editor, Senior Moderator
NPJ Vaccines
. 2021 Aug 4;6(1):95.
doi: 10.1038/s41541-021-00359-8.
Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges
Andrew Chak-Yiu Lee[SUP] 1 [/SUP], Anna Jinxia Zhang[SUP] 1 2 3 [/SUP], Can Li[SUP] 1 [/SUP], Yanxia Chen[SUP] 1 [/SUP], Feifei Liu[SUP] 1 [/SUP], Yan Zhao[SUP] 1 [/SUP], Hin Chu[SUP] 1 [/SUP], Carol Ho-Yan Fong[SUP] 1 [/SUP], Pui Wang[SUP] 1 [/SUP], Siu-Ying Lau[SUP] 1 [/SUP], Kelvin Kai-Wang To[SUP] 1 2 3 [/SUP], Honglin Chen[SUP] 1 2 3 [/SUP], Kwok-Yung Yuen[SUP] 4 5 6 [/SUP]
Affiliations
Abstract
We previously developed a temperature-sensitive, and NS1 gene deleted live attenuated influenza vaccine (DelNS1-LAIV) and demonstrated its potent protective efficacy in intranasally vaccinated mice. Here we investigated whether intradermal (i.d.) vaccination induces protective immunity. Our results showed that DelNS1-LAIV intradermal vaccination conferred effective and long-lasting protection against lethal virus challenge in mice. A single intradermal injection of DelNS1-LAIV conferred 100% survival with no weight loss in mice after A(H1N1)09 influenza virus (H1N1/415742Md) challenge. DelNS1-LAIV injection resulted in a significant reduction of lung viral load and reduced airway epithelial cell death and lung inflammatory cytokine responses at day 2 and 4 post challenge. Full protections of mice lasted for 6 months after immunization. In vitro infection of DelNS1-LAIV in monocyte-derived dendritic cells (MoDCs) demonstrated activation of antigen-presenting cells at 33 °C, together with the results of abortive replication of DelNS1-LAIV in skin tissue and strong upregulation of inflammatory cytokines/chemokines expression, our results suggested the strong immunogenicity of this vaccine. Further, we demonstrate that the underlying protection mechanism induced by intradermal DelNS1-LAIV is mainly attributed to antibody responses. Together, this study opens up an alternative route for the administration of LAIV, which may benefit individuals not suitable for intranasal LAIV immunization.
. 2021 Aug 4;6(1):95.
doi: 10.1038/s41541-021-00359-8.
Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges
Andrew Chak-Yiu Lee[SUP] 1 [/SUP], Anna Jinxia Zhang[SUP] 1 2 3 [/SUP], Can Li[SUP] 1 [/SUP], Yanxia Chen[SUP] 1 [/SUP], Feifei Liu[SUP] 1 [/SUP], Yan Zhao[SUP] 1 [/SUP], Hin Chu[SUP] 1 [/SUP], Carol Ho-Yan Fong[SUP] 1 [/SUP], Pui Wang[SUP] 1 [/SUP], Siu-Ying Lau[SUP] 1 [/SUP], Kelvin Kai-Wang To[SUP] 1 2 3 [/SUP], Honglin Chen[SUP] 1 2 3 [/SUP], Kwok-Yung Yuen[SUP] 4 5 6 [/SUP]
Affiliations
- PMID: 34349128
- DOI: 10.1038/s41541-021-00359-8
Abstract
We previously developed a temperature-sensitive, and NS1 gene deleted live attenuated influenza vaccine (DelNS1-LAIV) and demonstrated its potent protective efficacy in intranasally vaccinated mice. Here we investigated whether intradermal (i.d.) vaccination induces protective immunity. Our results showed that DelNS1-LAIV intradermal vaccination conferred effective and long-lasting protection against lethal virus challenge in mice. A single intradermal injection of DelNS1-LAIV conferred 100% survival with no weight loss in mice after A(H1N1)09 influenza virus (H1N1/415742Md) challenge. DelNS1-LAIV injection resulted in a significant reduction of lung viral load and reduced airway epithelial cell death and lung inflammatory cytokine responses at day 2 and 4 post challenge. Full protections of mice lasted for 6 months after immunization. In vitro infection of DelNS1-LAIV in monocyte-derived dendritic cells (MoDCs) demonstrated activation of antigen-presenting cells at 33 °C, together with the results of abortive replication of DelNS1-LAIV in skin tissue and strong upregulation of inflammatory cytokines/chemokines expression, our results suggested the strong immunogenicity of this vaccine. Further, we demonstrate that the underlying protection mechanism induced by intradermal DelNS1-LAIV is mainly attributed to antibody responses. Together, this study opens up an alternative route for the administration of LAIV, which may benefit individuals not suitable for intranasal LAIV immunization.